Background: To investigate the gene expression profile of a set of candidate genes for a better understanding of the molecular mechanism underlying the pathogenesis of thymoma with or without myasthenia gravis.
Methods: Thymoma patients and thymoma patients with myasthenia gravis were analyzed using microarray profiling to identify significant changes in gene expression of autoimmune regulator pathway genes including AIRE, IL-7R, CHRNA3, SYMD1, THRA, and CAV3.
Results: Across all of our samples, we found that 1484 mRNAs were upregulated and 770 were downregulated in thymoma patients compared with thymoma with myasthenia gravis patients. Gene ontology and pathway analysis revealed that a large number of genes participated in cellular functions for humoral immune response, sequence-specific DNA binding RNA polymerase II transcription factor activity, positive regulation of gene expression, regulation of neuron projection development, extracellular ligand-gated ion channel activity, positive regulation of striated muscle cell differentiation, and regulation of nuclear factor-kappaB import into the nucleus.
Conclusion: Our results revealed genetic differences between thymomas and myasthenia gravis, and identified the key candidate genes/pathways for molecular mechanism.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397909 | PMC |
http://dx.doi.org/10.1111/1759-7714.12980 | DOI Listing |
Neurol Sci
January 2025
Neurology Unit, Ospedale A. Manzoni, ASST Lecco, Via Dell'Eremo 9-11, Lecco, 23900, Italy.
Muscle Nerve
January 2025
Department of Neurology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, New York, USA.
Introduction/aims: Neonatal Fc receptor (FcRn) inhibitors represent a promising treatment option for patients with generalized myasthenia gravis (gMG); however, data on clinical use are limited. The aim of this report is to describe one center's approach to efgartigimod dosing in patients with gMG.
Methods: Medical records of patients with acetylcholine receptor antibody-positive (AChR-Ab+) gMG whose symptoms were not adequately controlled by oral medications and/or intravenous immunoglobulin who received efgartigimod between January 2022 and January 2024 were retrospectively evaluated.
Curr J Neurol
April 2024
Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Stress has been known as a risk factor for the onset and modification of autoimmune disorders such as myasthenia gravis (MG). However, the patients can control their stress and improve their quality of life (QOL) using some factors such as psychological and social support. Psychological capital and social support play a key role in decreasing stress and improving QOL in the patients with MG.
View Article and Find Full Text PDFZhonghua Yan Ke Za Zhi
January 2025
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing100730, China.
Immune checkpoint inhibitors (ICI), as a new type of targeted therapeutic drugs, have demonstrated durable efficacy in cancer treatment. However, some patients receiving ICI treatment may be affected by immune-related adverse events (irAE). Compared with irAE in skin tissues, gastrointestinal system, etc.
View Article and Find Full Text PDFJ Neurol Sci
December 2024
Liaoning University of Traditional Chinese Medicine, Shenyang, China; Department of Neurology, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!